U2Bio Co., Ltd. (KOSDAQ:221800)

U2Bio Statistics

Total Valuation

U2Bio has a market cap or net worth of KRW 302.72 billion. The enterprise value is 271.39 billion.

Market Cap	302.72B
Enterprise Value	271.39B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 29, 2025

Share Statistics

U2Bio has 15.93 million shares outstanding. The number of shares has increased by 3.32% in one year.

Current Share Class	15.93M
Shares Outstanding	15.93M
Shares Change (YoY)	+3.32%
Shares Change (QoQ)	+12.71%
Owned by Insiders (%)	38.29%
Owned by Institutions (%)	n/a
Float	8.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.83
PB Ratio	7.16
P/TBV Ratio	7.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-165.28
EV / Sales	10.60
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-164.09

Financial Position

The company has a current ratio of 6.39, with a Debt / Equity ratio of 0.01.

Current Ratio	6.39
Quick Ratio	6.24
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.27
Interest Coverage	-58.87

Financial Efficiency

Return on equity (ROE) is -4.28% and return on invested capital (ROIC) is -29.99%.

Return on Equity (ROE)	-4.28%
Return on Assets (ROA)	-2.81%
Return on Invested Capital (ROIC)	-29.99%
Return on Capital Employed (ROCE)	-4.76%
Weighted Average Cost of Capital (WACC)	13.80%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.53
Inventory Turnover	27.56

Taxes

In the past 12 months, U2Bio has paid 318.89 million in taxes.

Income Tax	318.89M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +486.16% in the last 52 weeks. The beta is 1.74, so U2Bio's price volatility has been higher than the market average.

Beta (5Y)	1.74
52-Week Price Change	+486.16%
50-Day Moving Average	12,319.80
200-Day Moving Average	5,869.80
Relative Strength Index (RSI)	49.78
Average Volume (20 Days)	2,828,722

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, U2Bio had revenue of KRW 25.59 billion and -1.64 billion in losses. Loss per share was -141.00.

Revenue	25.59B
Gross Profit	5.39B
Operating Income	-2.19B
Pretax Income	-1.32B
Net Income	-1.64B
EBITDA	-1.36B
EBIT	-2.19B
Loss Per Share	-141.00

Balance Sheet

The company has 31.77 billion in cash and 442.62 million in debt, with a net cash position of 31.32 billion or 1,966.06 per share.

Cash & Cash Equivalents	31.77B
Total Debt	442.62M
Net Cash	31.32B
Net Cash Per Share	1,966.06
Equity (Book Value)	42.30B
Book Value Per Share	3,325.28
Working Capital	34.62B

Cash Flow

In the last 12 months, operating cash flow was -1.56 billion and capital expenditures -91.62 million, giving a free cash flow of -1.65 billion.

Operating Cash Flow	-1.56B
Capital Expenditures	-91.62M
Depreciation & Amortization	834.91M
Net Borrowing	-415.90M
Free Cash Flow	-1.65B
FCF Per Share	-103.81

Margins

Gross margin is 21.08%, with operating and profit margins of -8.56% and -6.42%.

Gross Margin	21.08%
Operating Margin	-8.56%
Pretax Margin	-5.17%
Profit Margin	-6.42%
EBITDA Margin	-5.30%
EBIT Margin	-8.56%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 0.43%.

Dividend Per Share	100.00
Dividend Yield	0.43%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-3.32%
Shareholder Yield	-2.89%
Earnings Yield	-0.54%
FCF Yield	-0.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 23, 2023. It was a forward split with a ratio of 4.

Last Split Date	Feb 23, 2023
Split Type	Forward
Split Ratio	4

Scores

U2Bio has an Altman Z-Score of 3.91 and a Piotroski F-Score of 2.

Altman Z-Score	3.91
Piotroski F-Score	2